We are live on ! Find out more
ESLAW icon

Estrella Immunopharma Warrant
ESLAW

19 hedge funds and large institutions have $2.24M invested in Estrella Immunopharma Warrant in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

6% more funds holding

Funds holding: 18 → 19 (+1)

0% less capital invested

Capital invested by funds: $2.25M → $2.24M (-$3.91K)

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
1
Closed
1
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.69K
2
Citadel Advisors
Citadel Advisors
Florida
+$3.48K
3
RCM
Robinson Capital Management
Michigan
+$807
4
CS
Clear Street
New York
+$82
5
UBS Group
UBS Group
Switzerland
+$14

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$8.6K
2
CH
CVI Holdings
Delaware
-$7
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$2.19M – – –
ASM
2
ATW SPAC Management
New York
$10.2K – – –
EFI
3
EHP Funds Inc
Canada
$9.03K – – –
CH
4
CVI Holdings
Delaware
$4.78K -$7 -100 -0.1%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$4.35K +$3.69K +54,010 +222%
YCM
6
Yakira Capital Management
Connecticut
$3.5K – – –
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$3.45K – – –
SIA
8
SkyView Investment Advisors
New Jersey
$3K – – –
RCM
9
Radcliffe Capital Management
Pennsylvania
$2.62K – – –
WA
10
Whitebox Advisors
Minnesota
$2.52K – – –
SOA
11
Sea Otter Advisors
Florida
$2.22K – – –
Hudson Bay Capital Management
12
Hudson Bay Capital Management
Connecticut
$2.05K – – –
Citadel Advisors
13
Citadel Advisors
Florida
$2.01K +$3.48K +50,920 New
RCM
14
Robinson Capital Management
Michigan
$1.68K +$807 +11,805 +100%
CS
15
Clear Street
New York
$1.6K +$82 +1,200 +4%
SSA
16
Schonfeld Strategic Advisors
New York
$1.02K – – –
LCM
17
Landscape Capital Management
New Jersey
$759 – – –
Bank of America
18
Bank of America
North Carolina
$16 – – –
UBS Group
19
UBS Group
Switzerland
$8 +$14 +200 New
KPF
20
K2 Principal Fund
Ontario, Canada
– -$8.6K -118,936 Closed

ESLAW Hedge Fund Activity: Q2 2023 in Review

19 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q2 2023, worth a combined $2.24M — down 0.17% from $2.25M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ESLAW positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $3.69K. The largest seller was K2 Principal Fund, exiting entirely with an estimated $8.6K sold.

  • 19 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q2 2023, up from 18 in Q1 2023.
  • Funds reported $2.24M of Estrella Immunopharma Warrant stock for Q2 2023, down 0.17% quarter-over-quarter.
  • 2 funds opened new Estrella Immunopharma Warrant positions in Q2 2023 and 1 closed out, a net change of +1 holder.
  • The largest Estrella Immunopharma Warrant buyer in Q2 2023 was Susquehanna International Group, an estimated $3.69K added.
  • The largest Estrella Immunopharma Warrant seller in Q2 2023 was K2 Principal Fund, an estimated $8.6K sold.

Based on aggregated 13F filings for Q2 2023.